Clinical Trials Logo
  1. Home
  2. Gastric Cancer Stage IV
  3. NCT05301465

Predictive Role of Circulating Angiogenic Factors for Second-line Paclitaxel and Ramucirumab.

Gastric Cancer Stage IV Clinical Trial

Official title:
Prospective Study to Identify and Validate the Predictive Role of Circulating Angiogenic Factors in Patients With Metastatic Gastric Cancer Treated With Second-line Paclitaxel and Ramucirumab

Clinical Trial Summary

The project is primarily aimed at identifying and subsequently validating the predictive role of plasma concentrations of VEGF-A (vascular endothelial growth factor A), VEGF-D (vascular endothelial growth factor D) and s-VEGFR2 (soluble Vascular Endothelial Growth Factor Receptor 2) measured prior to initiation and during second-line treatment with paclitaxel and ramucirumab in patients with unresectable gastric cancer pretreated with first-line chemotherapy. For the primary endpoint, the efficacy parameter chosen is PFS, calculated from day 1 of treatment to date of progression or death.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05301465
Study type Observational
Source University of Pisa
Contact
Status Recruiting
Phase
Start date November 1, 2021
Completion date June 1, 2023
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04592211 - Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer With HRR Mutation and MSS Phase 1/Phase 2
Active, not recruiting NCT06034964 - Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC
Recruiting NCT05204173 - Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis Phase 2
Active, not recruiting NCT04267549 - Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer Phase 2
Recruiting NCT06342427 - Stomach Cancer Exosome-based Detection
Recruiting NCT04563975 - Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer Phase 2
Terminated NCT04168931 - Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC Phase 2
Recruiting NCT03701373 - Maintenance Treatment With S-1 in Gastric Cancer Patients Phase 2
Recruiting NCT05319639 - Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab Phase 1/Phase 2
Completed NCT03618758 - Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6 Phase 1/Phase 2
Completed NCT03755440 - PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients. Phase 2
Completed NCT03159585 - To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors Phase 1